Protalix BioTherapeutics is a biopharmaceutical company engaged in developing and commercializing recombinant therapeutic proteins expressed through ProCellEx, a proprietary plant cell-based expression system. Using ProCellEx, the company is developing and commercializing a proprietary pipeline of novel and biosimilar proteins that target large, established pharmaceutical markets and rely on known biological action mechanisms. The company’s initial commercial focus is on complex therapeutic proteins to treat genetic disorders like Gaucher disease and Fabry disease. For more information, visit the company’s Web site at www.protalix.com.

The BIO CEO & Investor Conference is the largest investor conference focused on established and emerging publicly traded biotech companies. Each year the annual event provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. For more information on Biotechnology Industry Organization (BIO), visit www.bio.org.

Let us hear your thoughts below: